Beng-Jing Wu

Beng-Jing Wu

Auto-generated profile, based on publicly available information

Beng-Jing Wu

Metabolic Research Centre, University of Wollongong, Wollongong, NSW 2522 Australia

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Yutang WangYutang Wang
Yutang Wang
HLHanzhong Liu
Hanzhong Liu
GMGavin McKenzie
Gavin McKenzie
Paul WittingPaul Witting
Paul Witting
JSJohannes-Peter Stasch
Johannes-Peter Stasch
RSRoland Stocker
Roland Stocker

10 April 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
BWBen J. Wu
Ben J. Wu
KKKrishna Kathir
Krishna Kathir
Paul WittingPaul Witting
Paul Witting
KBKonstanze Beck
Konstanze Beck
KCKatherine Choy
Katherine Choy
RSRoland Stocker
Roland Stocker
Oxidative stress is implicated in atherogenesis, yet most clinical trials with antioxidants, particularly vitamin E, have failed to protect against atherosclerotic diseases. A striking exception is probucol, which retards atherosclerosis in carotid arteries and restenosis of coronary arteries after angioplasty. Because probucol has in vitro cellular-protective effects independent of inhibiting lipid oxidation, we investigated the mode of action of probucol in vivo. We used three models of vascular disease: apolipoprotein E–deficient mice, a model of atherosclerosis; rabbit aortic balloon injury, a model of restenosis; and carotid injury in obese Zucker rats, a model of type 2 diabetes. Unexpectedly, we observed that the phenol moieties of probucol were insufficient, whereas its sulphur atoms were required for protection. Probucol and its sulphur-containing metabolite, but not a sulphur-free phenolic analogue, protected via cell-specific effects on inhibiting macrophage accumulation, stimulating reendothelialization, and inhibiting vascular smooth muscle cell proliferation. These processes were mediated via induction of heme oxygenase-1 (HO-1), an activity not shared by vitamin E. Our findings identify HO-1 as the molecular target of probucol. They indicate 2-electron rather than radical (1-electron) oxidants as important contributors to atherogenesis, and point to novel lead compounds for therapeutic intervention against atherosclerotic diseases.

1 May 2010 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
BWBen J. Wu
Ben J. Wu
LYLing Yan
Ling Yan
FCFrancesca Charlton
Francesca Charlton
Paul WittingPaul Witting
Paul Witting
PBPhilip J. Barter
Philip J. Barter
KRKerry-Anne Rye
Kerry-Anne Rye
Objective— To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels. Methods and Results— New Zealand white rabbits received normal chow or chow supplemented with 0.6% or 1.2% (wt/wt) niacin. This regimen had no effect on plasma cholesterol, triglyceride, or high-density lipoprotein levels. Acute vascular inflammation and endothelial dysfunction were induced in the animals with a periarterial carotid collar. At the 24-hour postcollar implantation, the endothelial expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemotactic protein-1 was markedly decreased in the niacin-supplemented animals compared with controls. Niacin also inhibited intima-media neutrophil recruitment and myeloperoxidase accumulation, enhanced endothelial-dependent vasorelaxation and cyclic guanosine monophosphate production, increased vascular reduced glutathione content, and protected against hypochlorous acid–induced endothelial dysfunction and tumor necrosis factor α–induced vascular inflammation. Conclusion— Previous human intervention studies have demonstrated that niacin inhibits coronary artery disease. This benefit is thought to be because of its ability to reduce low-density lipoprotein and plasma triglyceride levels and increase high-density lipoprotein levels. The present study showed that niacin inhibits vascular inflammation and protects against endothelial dysfunction independent of these changes in plasma lipid levels.

1 June 2011 in SLEEP
Verified
Journal Article
Open access
PDF file
JCJin-Gun Cho
Jin-Gun Cho
Paul WittingPaul Witting
Paul Witting
MVManisha Verma
Manisha Verma
BWBen J. Wu
Ben J. Wu
ASAnu Shanu
Anu Shanu
JWJohn R. Wheatley
John R. Wheatley
Study Objectives:. We have previously identified heavy snoring as an independent risk factor for carotid atherosclerosis. In order to explore the hypot

1 January 2018 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
SSSudichhya Shrestha
Sudichhya Shrestha
BWBen J. Wu
Ben J. Wu
LGLiam Guiney
Liam Guiney
PBPhilip J. Barter
Philip J. Barter
KRKerry-Anne Rye
Kerry-Anne Rye
Most of the cholesterol in plasma is in an esterified form that is generated in potentially cardioprotective high density lipoproteins (HDLs). Cholesteryl ester transfer protein (CETP) mediates bidirectional transfers of cholesteryl esters (CE) and triglycerides (TG) between plasma lipoproteins. Since CE originates in HDLs, and TG enters the plasma as a component of very low density lipoproteins (VLDLs), activity of CETP results in a net mass transfer of CE from HDLs to VLDLs and low density lipoproteins (LDLs), and of TG from VLDLs to LDLs and HDLs. As inhibition of CETP activity increases the concentration of HDL cholesterol and decreases the concentration of VLDL and LDL cholesterol, it has the potential to reduce atherosclerotic cardiovascular disease. This has led to the development of anti-CETP neutralising monoclonal antibodies, vaccines and anti-sense oligonucleotides. Small molecule inhibitors of CETP have also been developed and four of them have been studied in large scale cardiovascular clinical outcome trials. This review describes the structure of CETP and its mechanism of action. Details of its regulation and non-lipid transporting functions are discussed, and the results of the large scale clinical outcome trials of small molecule CETP inhibitors are summarised.

28 September 2004 in Circulation
Verified
Journal Article
Closed access
YDYi-Mo Deng
Yi-Mo Deng
BWBen J. Wu
Ben J. Wu
Paul WittingPaul Witting
Paul Witting
RSRoland Stocker
Roland Stocker
Background— Evidence suggests that induction of heme oxygenase-1 (HO-1) inhibits proliferation of vascular smooth muscle cells and intimal thickening after arterial injury, and therapeutic molecules induce HO-1. Probucol is the only oral drug that inhibits restenosis in humans and intimal thickening in animals, although its underlying mechanism remains unclear. Methods and Results— Aortas were harvested from New Zealand White rabbits fed normal or 0.75% (wt/wt) probucol-fortified chow, with or without endothelial denudation of the abdominal aorta on day 21, and analyzed for heme oxygenase and apoptosis. Uninjured aortas were harvested on day 21 and balloon-injured aortas on days 22 and 25. Probucol significantly increased mRNA of HO-1 assessed by real-time PCR and HO activity in aortas at all time points. Probucol also enhanced apoptosis of medial cells in the injured aorta, as evidenced by the TUNEL assay. Furthermore, probucol (100 μmol/L) increased HO-1 mRNA and HO activity when added to rabbit aortic smooth muscle cells (RASMCs) cultured in serum-free medium for 24 hours. Induction of HO-1 mRNA was inhibited by actinomycin D and was associated with inhibition of RASMC proliferation. This probucol-induced increase in HO-1 mRNA and inhibition of RASMC proliferation was prevented by the HO inhibitor Sn(IV) protoporphyrin or transfection with small interference RNA (siRNA) to knockdown HO-1, but not by inactive Cu(II) protoporphyrin or scrambled siRNA. Conclusions— Probucol induces HO-1, and this contributes to the inhibition of vascular SMC proliferation. This novel finding may explain how probucol inhibits restenosis and highlights HO-1 as a target for therapeutic intervention against occlusive vascular disease.